Intracell Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 0.10 M
as on 26-07-2024
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 113.53%
(FY 2023)
- Profit -1564.76%
(FY 2023)
- Ebitda -930.10%
(FY 2023)
- Net Worth -173.97%
(FY 2023)
- Total Assets 539.52%
(FY 2023)
About Intracell Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammed Sadiq and Mirza Baig serve as directors at the Company.
- CIN/LLPIN
U24100MH2013PTC240329
- Company No.
240329
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Feb 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Intracell Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Sadiq  | Director | 11-Feb-2013 | Current |
| Mirza Baig | Director | 11-Feb-2013 | Current |
Financial Performance of Intracell Therapeutics.
Intracell Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 113.53% increase. The company also saw a substantial fall in profitability, with a 1564.76% decrease in profit. The company's net worth observed a substantial decline by a decrease of 173.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intracell Therapeutics?
In 2023, Intracell Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vitane Pharmaceuticals Private LimitedActive 18 years 4 monthsMohammed Sadiq and Mirza Baig are mutual person
Vitane Biologics Private LimitedActive 18 years 2 monthsMohammed Sadiq and Mirza Baig are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Intracell Therapeutics?
Intracell Therapeutics has a workforce of 1 employees as of Jul 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intracell Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intracell Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
